DGKL calls for strengthening preventive medicine for hepatitis B and C
The German Society for Clinical Chemistry and Laboratory Medicine (DGKL) has spoken out to Prof. Josef Hecken, the impartial chairman of the Federal Joint Committee (G-BA), in favour of a significant strengthening of preventive medicine in the field of hepatitis B and C (HBV/HCV). This is the result of an exchange between Hecken and DGKL President Prof. Mariam Klouche and DGKL Chairman Jan Wolter on 20 May 2026.
In particular, the DGKL advocates an extension of the Health Examination Directive. These include better risk stratification, target-group-specific targeting of at-risk groups, and accelerated surveillance for women at increased risk.

Another focus was cervical carcinoma. The professional society advocates a population-based screening strategy and greater involvement of younger women. The aim is to further improve the early detection of cervical cancer and to strengthen the quality assurance of examinations.
In the exchange, the DGKL emphasised the central role of laboratory medicine expertise in the implementation of modern, risk-adapted prevention programmes. The demands are to be incorporated into the further deliberations of the G-BA.
Read Also:
DGKL board member Jan Wolter calls for a total reset of the German healthcare system – MedLabPortal
Editor: X-Press Journalistenbüro GbR
Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability ected.




